Cybin Inc. Common Stock
HELPNASDAQHealthcareMedical - Pharmaceuticals
Previous close
$12.59
+$0.12 · +0.96%
HELP company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
22
Expensive
Momentum
64
Gaining
Sentiment
45
Mixed
Risk resilience
48
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteCybin Inc. functions as a biopharmaceutical company currently in its clinical development phase, concentrating on the advancement of novel therapeutic agents derived from psychedelic compounds. Its research pipeline includes CYB003, a deuterated psilocybin analog under investigation for major depressive disorder, and CYB004, a deuterated DMT compound being developed to address generalized anxiety disorder.
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- Headquarters
- CA
- CEO
- Michael Halstead
- Listed since
- Sep 13, 2019
- Employees
- 100
Market position
Day range
Current $12.59
52-week range
Current $12.59
- Open
- $12.58
- Previous close
- $12.47
- Volume
- 2.17M
- 1.46× average
- Average volume
- 1.49M
- Average daily volume
- Market cap
- 780.38M USD
- Beta
- 0.57
- Market reference 1
- 50-day average
- $7.7702
- +62.03% above average
- 200-day average
- $6.4298
- +95.81% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 9.28M USD
- P/E (TTM)
- -2.98×
- P/B (TTM)
- 2.71×
- P/S (TTM)
- 0×
- EV / EBITDA
- -0.07×
- Earnings yield
- -88.03%
- Free cash flow yield
- -80.08%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -63.32%
- Return on assets
- -58.36%
- Return on invested capital
- -60.93%
Financial health
- Debt / equity
- 0×
- Current ratio
- 9.52×
- Altman Z-score
- 32.94
- Piotroski F-score
- 3 of 9
Earnings
- EPS beat rate
- 27%
- 3 beats, 8 misses, 0 met estimates
- Average EPS surprise
- -39.27%
- 11 comparable reports
- Latest EPS result
- -0.91
- Estimate -0.84 · Miss by 8.84%
EPS: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Rating distribution
4 ratingsLimited analyst sample: 4 ratings. Interpret the distribution with caution.
Recent analyst actions
HELP peers
ETFs holding HELP
Funds reporting this stock among their holdings, ordered by reported position size.
AdvisorShares Psychedelics ETFPSIL- Market value
- 4.63M
- Weight
- 8.02%
- AUM
- 57.72M USD
- Expense ratio
- 1.84%
- Price / 1D
- $25.86-0.35%
Invesco NASDAQ Future Gen 200 ETFQQQS- Market value
- 306.84K
- Weight
- 1.35%
- AUM
- 22.98M USD
- Expense ratio
- 0.20%
- Price / 1D
- $45.0826+1.10%
T. Rowe Price Innovation Leaders ETFTNXT- Market value
- 10.69K
- Weight
- 0.06%
- AUM
- 18.54M USD
- Expense ratio
- 0.49%
- Price / 1D
- $28.5422-0.48%
Continue in GoAI
Research HELPresearch.disclaimer